Abstract
To the Editor: The COVID-19 pandemic caused by the severe acute respiratory syndrome virus (SARS-CoV-2) has led to uncertainty regarding the safety of immunosuppressive psoriasis therapy. We recently reported a meta-estimate that showed a 30% to 60% increase in the risk of respiratory tract infections (RTIs) in patients with psoriasis receiving interleukin (IL) 17 biologics compared to placebo.1 Similar to IL-17, IL-23 is a key cytokine in the maintenance of T-helper 17 cells, which mediate protection against pathogens.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
